New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 3, 2014
08:11 EDTPTLA, BAYRYPortola Pharmaceuticals enters into clinical collaboration agreement with Bayer
Portola Pharmaceuticals (PTLA) announced that it has entered into a second clinical collaboration agreement with Bayer HealthCare (BAYRY) and Janssen Pharmaceuticals to evaluate its investigational Factor Xa inhibitor reversal agent, andexanet alfa, in Phase 3 registration studies with the FDA-approved oral Factor Xa inhibitor XARELTO. Portola's original collaboration agreement with Bayer and Janssen, announced in February 2013, covered the conduct of a Phase 2 proof-of-concept study. Interim results of that study were presented in December 2013 at the 55th American Society of Hematology Annual Meeting and demonstrated that andexanet alfa can produce an immediate and dose-dependent reversal of the anticoagulation activity of XARELTO. The new clinical collaboration agreement will be in effect through completion of Phase 3 studies with XARELTO and any potential U.S. and EU regulatory approval of andexanet alfa. The Phase 3 studies are expected to start in the first half of 2014. Under this non-exclusive collaboration agreement, Portola will receive an upfront payment and is eligible to receive additional development and regulatory milestone payments. Portola retains full, worldwide commercial rights to andexanet alfa, which was designated as a breakthrough therapy by the FDA in November 2013 and for which Portola is pursuing an Accelerated Approval pathway.
News For PTLA;BAYRY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
08:36 EDTBAYRYZoetis guidance positive, says BMO Capital
Subscribe for More Information
November 18, 2014
05:43 EDTBAYRYRegeneron announces EYLEA injection approved for DME treatment in Japan
Subscribe for More Information
November 17, 2014
09:22 EDTPTLAOn The Fly: Pre-market Movers
Subscribe for More Information
08:13 EDTPTLAPortola, Bristol-Myers, Pfizer announce results from Phase 3 ANNEXA-A studies
Subscribe for More Information
November 14, 2014
07:14 EDTBAYRYAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
November 13, 2014
09:33 EDTBAYRYZoetis could get bought by Bayer for $53/share, says Jefferies
Subscribe for More Information
November 12, 2014
08:18 EDTBAYRYUBS to hold a conference
Subscribe for More Information
08:02 EDTPTLACredit Suisse to hold a conference
Subscribe for More Information
06:22 EDTBAYRYZoetis price target raised to $49 from $44 at Citigroup
Citigroup raised its price target for Zoetis (ZTS) shares to $49 after activist Pershing Square confirmed the accumulation of a 10% stake in the company. Citi thinks Pershing is interested in advocating for a sale of Zoetis, potentially to Valeant (VRX) if its bid for Allergan (AGN) fails. Citi believes others, including Bayer (BAYRY), could be interested in acquiring Zoetis. It keeps a Buy rating on the stock.
November 10, 2014
16:14 EDTPTLAPortola says advancing oral, dual Syk-JAK kinase inhibitor to next stage
"The third quarter marked another successful period of execution for Portola as we achieved a number of milestones across our three wholly-owned clinical programs. We announced positive Phase 3 study results with our universal Factor Xa inhibitor antidote, andexanet alfa, in which all primary and secondary endpoints were achieved with high statistical significance. We increased enrollment and remain on track to complete the betrixaban pivotal Phase 3 APEX Study by the end of 2015. In addition, we have made the decision to advance our oral, dual Syk-JAK kinase inhibitor, cerdulatinib, to the next stage of development based on the tolerability and clinical activity seen thus far in the ongoing Phase 1 study in patients with hematologic cancers," said William Lis, chief executive officer of Portola.
16:13 EDTPTLAPortola Pharmaceuticals reports Q3 EPS (86c), consensus (92c)
Subscribe for More Information
16:07 EDTBAYRYUBS to hold a conference
UBS European Conference is being held in London, England on November 11-12.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use